STAT Plus: How Gilead’s remdesivir price could come back to haunt the drug industry
Gilead Sciences, in a self-described effort to do “the right and responsible thing,” may have just set a precedent its industry peers will come to resent.
In picking a price for the Covid-19 drug remdesivir that is, in the words of CEO Daniel O’Day, “well below” its actual value, Gilead said it was prioritizing “broad and equitable access” over company profits.
Continue to STAT Plus to read the full story…
